Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis

被引:283
作者
Kothawala, Prajesh
Badamgarav, Enkhe
Ryu, Seonyoung
Miller, Ross M.
Halbert, R. J.
机构
[1] Cerner LifeSci, Beverly Hills, CA 90212 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90024 USA
关键词
D O I
10.4065/82.12.1493
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
OBJECTIVE: To quantify the adherence of patients to drug therapyfor osteoporosis in real-world settings via a systematic review and meta-analysis of observational studies. METHODS: The PubMed and Cochrane databases were searched for English-language observational studies published from January 1, 1990, to February 15, 2006, that assessed patient adherence to drug therapy for osteoporosis using the following medical subject headings and keywords: drug therapy, medication Adherence, medication persistence, medication possession ratio, patient compliance, and osteoporosis. Studies were stratified Into 3 groups: persistence (how long a patient continues therapy), compliance (how correctly, in terms of dose and frequency, a patient takes the medication), and adherence (a combination of persistence and compliance). A random-effects model was used to pool results from the selected studies. RESULTS: Twenty-four studies were included in the meta-analysis. The pooled database-derived persistence rate was 52% (95% confidence interval [CI], 44%-59%) for treatment lasting I to 6 months, 50% (95% CI, 37%-63%) for treatment lasting 7 to 12 months, 42% (95% CI, 20%-68%) for treatment lasting 13 to 24 months, returning to 52% (95% CI, 45%-58%) for treatment lasting more than 24 months. Pooled adherence rates decreased from 53% (95% CI, 52%-54%) for treatment lasting. 1 to 6 months to 43% for treatment lasting 7 to 12 months (95% CI, 38%-49%) or 13 to 24 months (43%; 95% CI, 32%-54%). The pooled refill compliance estimate was 68% (95% CI, 63%-72%) for treatment lasting 7 to 12 months and 68% (95% CI, 67%-69%) for treatment lasting 13 to 24 months. The pooled self-reported compliance rate was 62% (95% CI, 48%-75%) for treatment lasting I to 6 months and 66% (95% CI, 45%-81%) for treatment lasting 7 to 12 months. CONCLUSION: One-third to half of patients do not take their medication as directed. Nonadherence occurs shortly after treatment initiation. Terms and definitions need to be standardized to permit comparability of technologies designed to improve patient adherence. Prospective trials are, needed to assess the relationship between adherence And patient outcomes.
引用
收藏
页码:1493 / 1501
页数:9
相关论文
共 59 条
[1]
DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS [J].
ALTMAN, DG ;
LAUSEN, B ;
SAUERBREI, W ;
SCHUMACHER, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :829-835
[2]
[Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
[3]
Persistence of use of lipid-lowering medications - A cross-national study [J].
Avorn, J ;
Monette, J ;
Lacour, A ;
Bohn, RL ;
Monane, M ;
Mogun, H ;
LeLorier, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1458-1462
[4]
Beers MH, 2000, AM J MANAG CARE, V6, P1313
[5]
Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants [J].
Bosmans, Judith E. ;
Brook, Oscar H. ;
van Hout, Hein P. J. ;
de Bruijne, Martine C. ;
Nieuwenhuyse, Hugo ;
Bouter, Lex M. ;
Stalman, Wim A. B. ;
van Tulder, Maurits W. .
PHARMACOECONOMICS, 2007, 25 (01) :25-37
[6]
Gaps in treatment among users of osteoporosis medications: The dynamics of noncompliance [J].
Brookhart, M. Alan ;
Avorn, Jerry ;
Katz, Jeffrey N. ;
Finkelstein, Joel S. ;
Arnold, Marilyn ;
Polinski, Jennifer M. ;
Patrick, Amanda R. ;
Mogun, Helen ;
Solmon, Daniel H. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (03) :251-256
[7]
Cost effectiveness of an adherence-improving programme in hypertensive patients [J].
Brunenberg, Danielle E. M. ;
Wetzels, Gwenn E. C. ;
Nelemans, Patricia J. ;
Dirksen, Carmen D. ;
Severens, Johan L. ;
Stoffers, Henri E. J. H. ;
Schouten, Jan S. A. G. ;
Prins, Martin H. ;
de Leeuw, Peter W. ;
Joore, Manuela A. .
PHARMACOECONOMICS, 2007, 25 (03) :239-251
[8]
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 [J].
Burge, Russel ;
Dawson-Hughes, Bess ;
Solomon, Daniel H. ;
Wong, John B. ;
King, Alison ;
Tosteson, Anna .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (03) :465-475
[9]
Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey [J].
Carnevale, V ;
Nieddu, L ;
Romagnoli, E ;
Bona, E ;
Piemonte, S ;
Scillitani, A ;
Minisola, S .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (03) :478-483
[10]
The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008